Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Subodh Verma

Showing results (571-580 of 616) with videos related to

Pageof 62
Sort By:
European Heart Journal|March 30, 2020
Effects of dapagliflozin in DAPA-HF according to background heart failure therapyKieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 16, 2026
A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HFAlasdair D Henderson, Kieran F Docherty, Atefeh Talebi, et al.
Journal of the American College of Cardiology|August 30, 2022
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection FractionJawad H Butt, Toru Kondo, Pardeep S Jhund, et al.
European Journal of Heart Failure|November 4, 2025
Finerenone in patients with severe heart failure: The FINEARTS-HF trialRiccardo M Inciardi, Henri Lu, Brian L Claggett, et al.
Circulation. Heart Failure|January 29, 2026
Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HFJawad H Butt, Alasdair D Henderson, Pardeep S Jhund, et al.
JAMA Cardiology|November 12, 2023
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.
Journal of the American College of Cardiology|December 12, 2024
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HFJawad H Butt, Alasdair D Henderson, Pardeep S Jhund, et al.
JAMA Network Open|August 27, 2021
Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery: A Randomized Clinical TrialAndrew C T Ha, Subodh Verma, C David Mazer, et al.
Circulation|October 12, 2020
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HFPardeep S Jhund, Scott D Solomon, Kieran F Docherty, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 28, 2022
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled TrialHiddo J L Heerspink, Remo H M Furtado, Otavio Berwanger, et al.
Pageof 62

Showing results (571-580 of 616) with videos related to

Sort By:
Pageof 62
European Heart Journal|March 30, 2020
Effects of dapagliflozin in DAPA-HF according to background heart failure therapyKieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 16, 2026
A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HFAlasdair D Henderson, Kieran F Docherty, Atefeh Talebi, et al.
Journal of the American College of Cardiology|August 30, 2022
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection FractionJawad H Butt, Toru Kondo, Pardeep S Jhund, et al.
European Journal of Heart Failure|November 4, 2025
Finerenone in patients with severe heart failure: The FINEARTS-HF trialRiccardo M Inciardi, Henri Lu, Brian L Claggett, et al.
Circulation. Heart Failure|January 29, 2026
Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HFJawad H Butt, Alasdair D Henderson, Pardeep S Jhund, et al.
JAMA Cardiology|November 12, 2023
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.
Journal of the American College of Cardiology|December 12, 2024
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HFJawad H Butt, Alasdair D Henderson, Pardeep S Jhund, et al.
JAMA Network Open|August 27, 2021
Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery: A Randomized Clinical TrialAndrew C T Ha, Subodh Verma, C David Mazer, et al.
Circulation|October 12, 2020
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HFPardeep S Jhund, Scott D Solomon, Kieran F Docherty, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 28, 2022
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled TrialHiddo J L Heerspink, Remo H M Furtado, Otavio Berwanger, et al.
Pageof 62